Cancer News and Research

Latest Cancer News and Research

NKCC1 protein may hold clues to how glioblastoma moves and invades

Johns Hopkins researchers have discovered that a protein that transports sodium, potassium and chloride may hold clues to how glioblastoma, the most common and deadliest type of brain cancer, moves and invades nearby healthy brain tissue.

2 May 2012

SCPC accredits Porter Adventist Hospital as Chest Pain Center

The Society of Chest Pain Centers (SCPC) recently awarded Porter Adventist Hospital full accreditation status as a Chest Pain Center.

2 May 2012

Beta-carotene-derived molecules have opposite effect in the body

New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.

2 May 2012

Vanity and fashion trends affect women's health

Fashion trends and concerns about appearance could be having a detrimental effect on the health and fitness of our nation's women according to a new survey commissioned by Cancer Research UK's Race for Life, in partnership with Tesco.

2 May 2012

Cancer genomes in a common database and computation of disease drivers

The emerging field of "personalized" or "precision" medicine holds great promise in the fight against cancer. If scientists can identify the genetic changes that drive each patient's cancer cells, they can use that information to develop targeted treatments. But achieving this goal will require massive amounts of genomic and clinical data and a sophisticated infrastructure to manage and analyze the data.

2 May 2012

Non-toxic green tea shampoo to treat dandruff

Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

Exact Sciences first quarter net loss increases to $10.6 million

Exact Sciences Corp. today announced its financial results for the quarter ended March 31, 2012.

2 May 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

Chemo-radiotherapy combination a viable alternative for frail bladder cancer patients

Bladder cancer patients given low doses of chemotherapy combined with radiotherapy were nearly 50 per cent less likely to relapse with the most lethal form of the disease compared to those given radiotherapy alone, a major trial funded by Cancer Research UK shows.

2 May 2012

CHR-3996 pill shows promise against advanced cancers

Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.

2 May 2012

Weight loss reduces inflammation in postmenopausal women

Postmenopausal women who were overweight or obese and lost at least 5 percent of their body weight had a measurable reduction in markers of inflammation, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

2 May 2012

Seed localization improves satisfaction of breast cancer patients

A cutting-edge procedure called seed localization is improving patient satisfaction at The Dubin Breast Center of the Tisch Cancer Institute at The Mount Sinai Medical Center. In patients undergoing lumpectomy for cancers that are small and cannot be felt in the breast, a tiny radioactive seed is guided into the breast and implanted at the site of the tumor.

2 May 2012

Tyrosine kinases could act as drivers for growth and survival of sarcomas

To better understand the signaling pathways active in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art mass spectrometry-based proteomics to characterize a family of protein enzymes that act as "on" or "off" switches important in the biology of cancer. The tyrosine kinases they identified, the researchers said, could act as "drivers" for the growth and survival of sarcomas.

2 May 2012

LUHS to celebrate Nurses Week from May 7- 11

Loyola University Health System (LUHS) will celebrate Nurses Week from May 7- 11. The theme for the week, "Healthy Nurses, Healthy Teams, Healthy Patients," celebrates all that nurses do to improve the health of their patients and the community.

2 May 2012

Lixte submits IND with FDA to conduct LB-100 Phase I trial for cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.

2 May 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

Roundup: Mass. premium increases muted; Iowa cuts payment to charity after fraud probe; Ga. asks EMS providers to save scarce drugs

State regulators on Monday approved third-quarter health insurance rates that will raise premiums an average of just 1.2 percent in the market serving small businesses and individuals, continuing a trend of more modest increases seen over the past three quarters. And several carriers, including Tufts Health Plan of Watertown and Fallon Community Health Plan, based in Worcester, will reduce their rates -- a rarity in Massachusetts health care -- according to data from the state Division of Insurance.

2 May 2012

FDA clears ProUroCare’s new prostate mechanical imaging system

ProUroCare Medical Inc., provider of proprietary medical imaging products, announced today it has received clearance from the U.S. Food & Drug Administration (FDA) for its ProUroScan prostate mechanical imaging (PMI) system.

2 May 2012

First Edition: May 1, 2012

Today's health policy headlines include reports from the presidential campaign trail and from states on issues ranging from Massachusetts' payment reform to Idaho's scope-of-practices issues.

2 May 2012